ENGN Stock Analysis: Buy, Sell, or Hold?
ENGN - enGene Holdings Inc. Common Stock
$1.77
-0.02 (-1.12%)
▼
5d:
+0.57%
30d:
-0.56%
90d:
-75.59%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Sep 10, 2026
Get Alerted When ENGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ENGN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ENGN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: ENGN is currently trading at $1.77, which is considered slightly low relative to its 30-day fair value range of $1.77 to $1.90.
Technical Outlook: Technically, ENGN is in a strong downtrend. Immediate support is located at $1.71, while resistance sits at $1.94.
Market Sentiment: ENGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.29 (+85.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ENGN is in a strong downtrend. Immediate support is located at $1.71, while resistance sits at $1.94.
Market Sentiment: ENGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (3th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $3.29 (+85.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.77 -
$1.90
Company Quality Score
48/100
(HOLD)
Options IV Signal
3th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 3th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 85.6% below Wall St target ($3.29)
Trading Range Analysis
30-Day Trading Range
$1.77 -
$1.90
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.22
(12.7%)
Support & Resistance Levels
Support Level
$1.71
Resistance Level
$1.94
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.26
Wall Street Target
$3.29
(+85.6%)
Share & Embed Analysis
Last updated: August 04, 2026 4:46 AM ET
Data refreshes hourly during market hours. Next update: 5:46 AM
Data refreshes hourly during market hours. Next update: 5:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ENGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
